We wouldn't blame Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) shareholders if they were a little worried about the fact that Bartholomew Canton, the Founder recently netted about US$1.1m selling shares at an average price of US$3.12. However, it's crucial to note that they remain very much invested in the stock and that sale only reduced their holding by 1.3%.
View our latest analysis for Ginkgo Bioworks Holdings
Ginkgo Bioworks Holdings Insider Transactions Over The Last Year
Notably, that recent sale by Bartholomew Canton is the biggest insider sale of Ginkgo Bioworks Holdings shares that we've seen in the last year. So what is clear is that an insider saw fit to sell at around the current price of US$3.09. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. We note that this sale took place at around the current price, so it isn't a major concern, though it's hardly a good sign.
Insiders in Ginkgo Bioworks Holdings didn't buy any shares in the last year. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
NYSE:DNA Insider Trading Volume October 8th 2022
I will like Ginkgo Bioworks Holdings better if I see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.
Insider Ownership Of Ginkgo Bioworks Holdings
For a common shareholder, it is worth checking how many shares are held by company insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. It's great to see that Ginkgo Bioworks Holdings insiders own 29% of the company, worth about US$1.6b. I like to see this level of insider ownership, because it increases the chances that management are thinking about the best interests of shareholders.
So What Do The Ginkgo Bioworks Holdings Insider Transactions Indicate?
Insiders haven't bought Ginkgo Bioworks Holdings stock in the last three months, but there was some selling. Looking to the last twelve months, our data doesn't show any insider buying. The company boasts high insider ownership, but we're a little hesitant, given the history of share sales. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Ginkgo Bioworks Holdings. In terms of investment risks, we've identified 3 warning signs with Ginkgo Bioworks Holdings and understanding these should be part of your investment process.
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
我們不會責怪銀杏生物工程控股公司(紐約證券交易所股票代碼:DNA)股東如果他們對巴塞洛繆·坎頓的創始人巴塞洛繆·坎頓最近以3.12美元的平均價格出售股票獲得約110萬美元的收益感到擔憂的話。然而,重要的是要注意到,他們仍然非常多地投資於股票,出售只減少了1.3%的持有量。
查看我們對銀杏生物工程控股公司的最新分析
銀杏生物工程控股公司去年的內幕交易
值得注意的是,巴塞洛繆·坎頓最近的出售是我們在過去一年中看到的最大規模的銀杏生物工程控股股票內幕出售。因此,很明顯,一位內部人士認為,以目前3.09美元左右的價格出售是合適的。雖然我們通常不喜歡看到內幕出售,但如果以更低的價格出售,人們更擔心的是。我們注意到,這筆交易的價格大約是目前的價格,所以這並不是一個主要的擔憂,儘管這不是一個好兆頭。
銀杏生物控股的內部人士去年沒有購買任何股票。你可以在下面看到過去12個月(由公司和個人)進行的內幕交易的直觀描述。如果你想知道到底是誰賣了,賣了多少錢,什麼時候賣的,只需點擊下面的圖表!
紐約證券交易所:DNA內幕交易量2022年10月8日
如果我看到一些大的內部收購,我會更喜歡銀杏生物控股。在我們等待的時候,看看這個免費最近有大量內幕收購的成長型公司名單。
銀杏生物工程控股公司的內部人所有權
對於一個普通股股東來説,公司內部人士持有多少股份值得一查。內部人持股比例較高往往會讓公司領導層更加關注股東利益。很高興看到銀杏生物控股公司的內部人士擁有該公司29%的股份,價值約16億美元。我喜歡看到這種程度的內部人持股,因為它增加了管理層考慮股東最佳利益的機會。
那麼,銀杏生物控股公司的內幕交易表明了什麼?
過去三個月,內部人士沒有買入銀杏生物科技控股公司的股票,但出現了一些拋售。展望過去12個月,我們的數據並未顯示有任何內部人士買入。該公司號稱擁有很高的內部人持股比例,但考慮到股票出售的歷史,我們有點猶豫。除了瞭解正在進行的內幕交易外,識別銀杏生物控股公司面臨的風險也是有益的。在投資風險方面,我們已經確定了三個警告信號與銀杏生物工程控股公司合作,並瞭解這些應該是您投資過程的一部分。
當然了,如果你把目光投向別處,你可能會發現這是一筆很棒的投資。所以讓我們來看看這個免費有趣的公司名單。
就本文而言,內部人是指向相關監管機構報告其交易的個人。我們目前負責公開市場交易和私人處置,但不包括衍生品交易。
對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫。或者,也可以給編輯組發電子郵件,地址是implywallst.com。
本文由Simply Wall St.撰寫,具有概括性。我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議。它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況。我們的目標是為您帶來由基本面數據驅動的長期重點分析。請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內。Simply Wall St.對上述任何一隻股票都沒有持倉。